Ideal Medical Technologies
Ideal Medical Technologies specializes in developing advanced glucose control systems for hospital ICU settings. Their flagship product, FUSION, is an AI-driven, closed-loop glucose management system designed to automate insulin and dextrose infusion, reducing nursing workload, minimizing errors, and improving patient outcomes. The company aims to enhance critical care through innovative, autonomous medical technology with future plans to expand control capabilities beyond glucose management.
Industries
Nr. of Employees
small (1-50)
Ideal Medical Technologies
Asheville, North Carolina, United States, North America
Patents
Products
Hospital-based closed-loop glucose control system
A hospital-grade closed-loop system that autonomously regulates intravenous insulin and dextrose to maintain patient glucose within clinician-set targets, with real-time analytics and configurable patient parameters.
Hospital-based closed-loop glucose control system
A hospital-grade closed-loop system that autonomously regulates intravenous insulin and dextrose to maintain patient glucose within clinician-set targets, with real-time analytics and configurable patient parameters.
Expertise Areas
- Closed-loop glucose control
- ICU inpatient glycemic management
- AI-driven medical device control systems
- Medical device integration with infusion therapy
Key Technologies
- Closed-loop control algorithms
- Artificial intelligence / machine learning for control
- Real-time glucose analytics
- Intravenous insulin and dextrose infusion control
News & Updates
In May 2023, IMT successfully completed the first-in-human safety study of the FUSION system, achieving excellent safety efficacy results, including an average percent time in range of 87.8%. The results were presented at the 2023 American Diabetes Association meeting.
Successfully completed a 24-hour meal challenge study demonstrating safety and efficacy of the FUSION system.
In May 2023, IMT successfully completed the first-in-human safety study of the FUSION system, achieving excellent safety efficacy results, including an average percent time in range of 87.8%. The results were presented at the 2023 American Diabetes Association meeting.
Successfully completed a 24-hour meal challenge study demonstrating safety and efficacy of the FUSION system.